Supplement

Toll-like receptor 5 deficiency diminishes doxorubicin-induced acute cardiotoxicity in mice Running title: TLR5 deficiency diminishes acute cardiotoxicity

Zhen-Guo Ma^{1,2*}, Chun-Yan Kong^{1,2}, Hai-Ming Wu^{1,2}, Peng Song^{1,2}, Xin Zhang^{1,2}, Yu-Pei Yuan^{1,2}, Wei Deng^{1,2}, Qi-Zhu Tang^{1,2*}

¹Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, RP China ²Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan 430060, RP China

Zhen-Guo Ma and Chun-Yan Kong contributed equally to this study

*Corresponding author: Zhen-Guo Ma, Department of Cardiology, Renmin Hospital of Wuhan University, Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan University at Jiefang Road 238, Wuhan 430060, RP China Tel.: +86 27 88073385; Fax: +86 27 88042292. E-mail: <u>zhengma@whu.edu.cn</u>

Qi-Zhu Tang, Department of Cardiology, Renmin Hospital of Wuhan University, Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan University at Jiefang Road 238, Wuhan 430060, RP China Tel.: +86 27 88073385; Fax: +86 27 88042292. E-mail: <u>gztang@whu.edu.cn</u>



Figure S1. TLR5 deficiency attenuates DOX-induced inflammatory response and apoptosis without affecting cardiac function in mice. (A) Experimental protocol. (B-D) The alterations of heart rate, LVIDd and SBP after DOX injection in mice (n=6). (E) The mRNA levels of inflammatory factors in mice (n=6). (F) Nuclear translocation of NF- κ B (n=6). (G) The protein expressions of pro/anti-apoptotic gene (n=6). **P*<0.05 versus WT Saline; **P*<0.05 versus WT DOX group.



Figure S2. FL exacerbates DOX-induced inflammation in mice. (A) TNF- α mRNA level (n=6). (B) IL-1 β mRNA level (n=6). **P*<0.05 versus the matched control. vehicle; [#]*P*<0.05 versus DOX group.



Figure S3. The production of ROS induced by DOX is TLR5 dependent. (A) Cell viability after FL treatment (n=6). (B-C) The production of hydrogen peroxide and superoxide (n=6). (D) The protein expression of MyD88 (n=6). (E) The protein expression of NOX2 after FL treatment (n=6). *P<0.05 versus the matched control.



Figure S4. The deficiency of NOX isoenzymes. (A) The protein expression of NOX isoenzymes (n=6). (B) The mRNA levels of DUOX1 and DUOX2 (n=6). **P*<0.05 versus the matched control.



Figure S5. TLR5 promotes DOX-induced inflammation via ROS production. (A-B) NF-KB

activation (n=6). (C) TNF- α mRNA level (n=6). **P*<0.05 versus matched control. The data are expressed as the mean ± SEM from three independent experiments.



Figure S6. NOX2 deficiency suppresses the inflammatory response caused by DOX in mice. (A-B) The mRNA levels of inflammatory factors in mice (n=6). **P*<0.05 versus matched control.

Figure S7



Figure S7. The protein expression of Syk in vitro (n=6). **P*<0.05 versus matched control.



Figure S8. p38 inhibition blockes the toxic effects of FL on cell viability in vitro. (A-C) The protein expressions of p38 (n=6). (D) Cell viability after p38 inhibition (n=6). *P<0.05 versus matched control.



Figure S9. TLR5 neutralizing antibody abolished the cardiac damage caused by DOX in mice. (A) Body weight change (n=10). (B) Ejection fraction (n=8). (C) CK-MB in DOX-treated mice (n=6). (D-E) 4-HNE and MDA production (n=6). (F) TUNEL staining (n=6). (G) The mRNA levels of inflammatory factors (n=6). *P<0.05 versus matched control; *P<0.05 versus DOX group.